Abstract:Background: Anxiety symptoms usually worsen depression and functional impairment. The present study was aimed to evaluate the impact of escitalopram on social function and quality of life in major depressive disorder (MDD) patients with anxiety symptoms. Patients and methods: Adult MDD patients with functional impairment (Sheehan Disability Scale [SDS] score >= 9) and anxiety symptoms (Hamilton Anxiety Rating Scale [HAM-A] score >= 14) received escitalopram (10-20 mg/day) for 8 weeks. Symptom status was assessed by SDS, Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form, Montgomery-Asberg Depression Rating Scale (MADRS), HAM-A, and Quick Inventory of Depressive Symptomatology Self Report scales. Safety was evaluated by treatment-emergent adverse events (TEAEs). Results: Overall, 208 (79.7%) of 261 enrolled patients completed the 8-week treatment. Mean (SD) SDS and Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form total scores were 17.4 (5.87) and 39.3 (14.43) at baseline, which improved to 7.6 (6.71) and 61.6 (15.80), respectively, at week 8. Totally, 59.2% of patients achieved functional remission (SDS <= 6) and 61.7% of patients achieved depression remission (MADRS <= 10) at week 8; 48.1% of patients achieved both functional and depression remission (SDS <= 6 and MADRS <= 10). The change in SDS total score was positively correlated with the change in MADRS and HAM-A total scores at each visit. Patient's baseline SDS score was related with depression score (regression coeflicient=0.40582, y=0.0005); remission of SDS was statistically related to a reduction of week 2 and week 6 HAM-A score (p<0.0001) and reduction of MADRS score (p<0.0001). Overall, 25.7% of patients reported r 1 TEAEs. Most frequently reported TEAEs were nausea (5.8%), diarrhea (2.3%), and dizziness (2.7%). Most TEAEs were mild to moderate in severity. Four patients reported serious TEAEs, two patients reported suicide attempts, and one patient completed suicide. Conclusion: Escitalopram (10-20 mg/day) treatment was efficacious in reducing depression, improving social function, and quality of life in MDD patients with anxiety symptoms. No new safety signals were identified.

Bupropion SR in the treatment of depression comorbid with anxiety:a randomized,double-blind clinical trial

Randomized,multicenter,double blind comparative trial of reboxetine in the treatment of depression with or without anxiety

Bupropion-sustained release in treatment of depression (72 patients) : a randomized, double-blind, doubledummy, multi-center clinical trial

Study of Bupropion Hydrochloride Tablet and Fluoxetine in Treatment of Depression Multicenter Clinical Trial

The efficacy and safety of venlafaxine XR in treating patients with major depression in a multicenter,open-label, 16 week study

Treatment with Bupropion Sustained Release Tablet in Patients with Depression:A Randomized,double-Blind,multi-center Clinical Trial

Efficacy and Safety of Bupropion Hydrochloride Extended-Release Versus Escitalopram Oxalate in Chinese Patients with Major Depressive Disorder: Results from a Randomized, Double-Blind, Non-Inferiority Trial.

Escitalopram and sertraline in treatment of depression with anxiety

Clinical effect of reboxetine in the treatment of anxiety in depressive patients

A Preliminary Randomized Controlled Trial of Different Treatment Regimens for Melancholic Depression

Safety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxiety.

Duloxetine Versus Paroxetine in the Treatment of Major Depressive Disorder: a Randomized Double-Blind Multicentre Controlled Study

A Preliminary Study of Different Treatment Strategies for Anxious Depression.

Clinical Evaluation of the Efficacy and Safety of Tandospirone Versus Sertraline Monotherapy for Social Anxiety Disorder: a Randomized Open‐label Trial

Comparison of Reboxetine with Fluoxetine in Treatment of Depression: a Randomized, Double-Blind, Multicenter Study

Comparison of Escitalopram with Citalopram in Treatment of Depression: a Randomized, Double-Blind, Multicenter Study

Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials

Comparative Efficacy and Safety of Escitalopram versus Desvenlafaxine in Postmenopausal Women with Depression and Anxiety: A Randomized, Open-Label, Comparative Trial

Effects of Tandospirone Augmentation in Major Depressive Disorder Patients with High Anxiety: A Multicenter, Randomized, Parallel-Controlled, Open-Label Study

Efficacy and Safety of Escitalopram in Treatment of Severe Depression in Chinese Population.

Does Bupropion Increase Anxiety?: A Naturalistic Study Over 12 Weeks